The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human β-amyloid precursor protein transgenic mice

Neurobiology of Aging

Volumn 25, Issue 10, 2004, Pages 1315-1321

  Lee, Joo Yong ^a   Friedman, Jonathan E ^b   Angel, Itzchak ^b   Kozak, Alex ^b   Koh, Jae Young ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b D Pharm Ltd   (Israel)

Author keywords

Alzheimer's disease; Amyloid plaque; Cerebral amyloid angiopathy; Cerebrum; Tg2576 mice

Indexed keywords

1,2 BIS(2 AMINOPHENYLOXY)ETHANE N,N,N',N' TETRAACETIC ACID N,N' BIS(2 OCTADECYLOXYETHYL) ESTER N,N' DISODIUM; DP 109; METAL CHELATE; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BRAIN; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; LIPOPHILICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN FUNCTION; SENILE PLAQUE; TRANSGENE; VASCULAR AMYLOIDOSIS;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CHELATING AGENTS; DISEASE MODELS, ANIMAL; EGTAZIC ACID; FEMALE; HUMANS; METALS; MICE; MICE, TRANSGENIC; MULTIPROTEIN COMPLEXES; RECOMBINANT PROTEINS; SENILE PLAQUES; TREATMENT OUTCOME;

EID: 4644238758     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2004.01.005     Document Type: Article

References (41)

1. Atwood C.S., Moir R.D., Huang X., Scarpa R.C., Bacarra N.M., Romano D.M., et al. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis. J. Biol Chem. 273:1998;12817-12826
2. Banks W.A., Kastin A.J. Peptides and the blood-brain barrier: lipophilicity as a predictor of permeability. Brain Res Bull. 15:1985;287-292
3. Bonina F.P., Arenare L., Palagiano F., Saija A., Nava F., Trombetta D., et al. Synthesis, stability, and pharmacological evaluation of nipecotic acid prodrugs. J Pharm Sci. 88:1999;561-567
4. Bush A.I., Multhaup G., Paradis M., Vonsattel J.P., Gusella J.F., Beyreuther K., et al. Rapid induction of Alzheimer Aβ amyloid formation by zinc. Science. 265:1994;1464-1467
5. Calhoun M.E., Burgermeister P., Phinney A.L., Stalder M., Tolnay M., Wiederhold K.H., et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci USA. 96:1999;14088-14093
6. Cherny R.A., Legg J.T., McLean C.A., Fairlie D.P., Huang X., Atwood C.S., et al. Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion. J. Biol Chem. 274:1999;23223-23228
7. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 30:2001;665-676
8. Cole T.B., Wenzel H.J., Kafer K.E., Schwartzkroin P.A., Palmiter R.D. Elimination of zinc from synaptic vesicles in the intact mouse brain by disruption of the ZnT3 gene. Proc. Natl. Acad. Sci. USA. 96:1999;1716-1721
9. Dahlgren K.N., Manelli A.M., Stine W.B. Jr., Baker L.K., Krafft G.A., LaDu M.J. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J. Biol Chem. 277:2002;32046-32053
10. Deguchi Y., Hayashi H., Fujii S., Naito T., Yokoyama Y., Yamada S., et al. Improved brain delivery of a nonsteroidal anti-inflammatory drug with a synthetic glyceride ester: a preliminary attempt at a CNS drug delivery system for the therapy of Alzheimer's disease. J. Drug Target. 8:2000;371-381
11. Fonte J., Miklossy J., Atwood C., Martins R. The severity of cortical Alzheimer's type changes is positively correlated with increased amyloid-β levels: resolubilization of amyloid-β with transition metal ion chelators. J. Alzheimer Dis. 3:2001;209-219
12. Frederickson C.J., Kasarskis E.J., Ringo D., Frederickson R.E. A quinoline fluorescence method for visualizing and assaying the histochemically reactive zinc (bouton zinc) in the brain. J. Neurosci Methods. 20:1987;91-103
13. Ghosh M.K., Mitra A.K. Enhanced delivery of 5-iodo-2′-deoxyuridine to the brain parenchyma. Pharm Res. 9:1992;1173-1176
14. Helmuth L. New Alzheimer's treatments that may ease the mind. Science. 297:2002;1260-1262
15. Hoshi M., Sato M., Matsumoto S., et al. Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β Proc Natl Acad Sci USA. 100:2003;6370-6375
16. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102
17. Huang X., Atwood C.S., Hartshorn M.A., Multhaup G., Goldstein L.E., Scarpa R.C., et al. The Aβ peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry. 38:1999;7609-7616
18. Huang X., Cuajungco M.P., Atwood C.S., Hartshorn M.A., Tyndall J.D., Hanson G.R., et al. Cu(II) potentiation of Alzheimer's Aβ neurotoxicity: correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol Chem. 274:1999;37111-37116
19. Kang J., Lemaire H.G., Unterbeck A., Noguchi A., Yasutake K., Yoshida N., et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 325:1987;733-736
20. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid-β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21:2001;372-381
21. Kozak A, Shapiro I. Lipophilic diesters of chelating agents. Int Pat Publ 1999;WO 99/16741.
22. Kuo Y.M., Kokjohn T.A., Beach T.G., Sue L.I., Brune D., Lopez J.C., et al. Comparative analysis of amyloid-β chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J. Biol Chem. 276:2001;12991-12998
23. Lee J.Y., Mook-Jung I., Koh J.Y. Histochemically reactive zinc in plaques of the Swedish β-amyloid precursor transgenic mice. J. Neurosci. 19(RC10):1999;1-5
24. Lee J.Y., Cole T.B., Palmiter R.D., Suh S.W., Koh J.Y. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci USA. 99:2002;7705-7710
25. Liu S.T., Howlett G., Barrow C.J. Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the Aβ peptide of Alzheimer's disease. Biochemistry. 38:1999;9373-9378
26. Lorenzo A., Yankner B.A. β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA. 91:1994;12243-12247
27. Lue L.F., Kuo Y.M., Roher A.E., Brachova L., Shen Y., Sue L., et al. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J. Pathol. 155:1999;853-862
28. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA. 82:1985;4245-4249
29. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., Cotman C.W. Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13:1993;1676-1687
30. Price D.L., Sisodia S.S. Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci. 21:1998;479-505
31. Regland B., Lehmann W., Abedini I., Blennow K., Jonsson M., Karlsson I., et al. Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord. 12:2001;408-414
32. Rottkamp C.A., Raina A.K., Zhu X., Gaier E., Bush A.I., Atwood C.S., et al. Redox-active iron mediates amyloid-β toxicity. Free Radic Biol Med. 30:2001;447-450
33. Sayre L.M., Perry G., Harris P.L., Liu Y., Schubert K.A., Smith M.A. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J. Neurochem. 74:2000;270-279
34. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 399:1999;A23-A31
35. Shinkai Y., Yoshimura M., Morishima-Kawashima M., Ito Y., Shimada H., Yanagisawa K., et al. Amyloid β-protein deposition in the leptomeninges and cerebral cortex. Ann Neurol. 42:1997;899-908
36. Teller J.K., Russo C., DeBusk L.M., Angelini G., Zaccheo D., Dagna-Bricarelli F., et al. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med. 2:1996;93-95
37. Van Dorpe J., Smeijers L., Dewachter I., Nuyens D., Spittaels K., Van Den Haute C., et al. Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons. Am J. Pathol. 157:2000;1283-1298
38. Wang J., Dickson D.W., Trojanowski J.Q., Lee V.M. The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol. 158:1999;328-337
39. Weller R.O., Massey A., Newman T.A., Hutchings M., Kuo Y.M., Roher A.E. Amyloid β accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J. Pathol. 153:1998;725-733
40. Wenzel H.J., Cole T.B., Born D.E., Schwartzkroin P.A., Palmiter R.D. Ultrastructural localization of zinc transporter-3 (ZnT-3) to synaptic vesicle membranes within mossy fiber boutons in the hippocampus of mouse and monkey. Proc Natl Acad Sci USA. 94:1997;12676-12681
41. Yang D.S., McLaurin J., Qin K., Westaway D., Fraser P.E. Examining the zinc binding site of the amyloid-β peptide. Eur J. Biochem. 267:2000;6692-6698